FDA Strengthens Inspections Of Chinese Drug Firms In Heparin Aftermath
This article was originally published in The Tan Sheet
Executive Summary
BEIJING - As FDA leaders select inspectors to deploy across three offices being set up in China, the agency is also preparing to ramp up the number of inspections and the level of scrutiny of Chinese drug manufacturers that export to the U.S
You may also be interested in...
Global Rx-360 Consortium Aims To Curb Supply Chain Threats
Drug manufacturers formed the Rx-360 consortium as a vanguard in protecting the global supply chain of ingredients for Rx and nonprescription drug products from threats like the heparin adulteration potentially linked to 146 U.S. deaths in 2008
Global Rx-360 Consortium Aims To Curb Supply Chain Threats
Drug manufacturers formed the Rx-360 consortium as a vanguard in protecting the global supply chain of ingredients for Rx and nonprescription drug products from threats like the heparin adulteration potentially linked to 146 U.S. deaths in 2008
Global Rx-360 Consortium Aims To Curb Supply Chain Threats
Drug manufacturers formed the Rx-360 consortium as a vanguard in protecting the global supply chain of ingredients for Rx and nonprescription drug products from threats like the heparin adulteration potentially linked to 146 U.S. deaths in 2008